We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam and Cubist Collaborates to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection

News   Jan 12, 2009

 
Alnylam and Cubist Collaborates to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection
 
 
 

RELATED ARTICLES

Drug Prevents Liver Scarring in People With HIV

News

A new study reports that the injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis (scarring) in people living with HIV.

READ MORE

Novel Strategy for Synthesizing Complex Natural Products

News

Scientists have succeeded in synthesizing two complex products from a group which could be used in the development of new drugs.

READ MORE

Further Calls for Diversity in Genomics Research

News

Broadening diversity among participants in human genomics research will maximize the potential of the field, say members of an international genomics consortium.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE